Blood Transfusion (for acute severe hemolysis)
Treatment for G6pd Deficiency
Typical Dosage: Varies by patient's hemoglobin level and clinical status
Effectiveness
90%
Safety Score
65%
Clinical Trials
0
Participants
0
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Varies by patient's hemoglobin level and clinical status
Time to Effect
Immediate (within hours of administration)
Treatment Duration
As needed during acute hemolytic crisis (typically 1-2 units over several hours)
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$1,500
Side Effect Mgmt:$0
Total Annual:$1,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
5
Comparison vs No blood transfusion during severe crisis
Cost Difference
$0/year
Same cost
QALY Difference
+5.00 QALYs
Better outcomes
Dominance
No dominance
Blood Transfusion (for acute severe hemolysis) Outcomes
for G6pd Deficiency
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+95%
Common Side Effects
Febrile non-hemolytic transfusion reaction
+1%
Allergic reaction
+0.5%
Delayed hemolytic transfusion reaction
+0.05%
Transfusion-associated circulatory overload (TACO)
+0.05%
Transfusion-related acute lung injury (TRALI)
+0.01%
Infection (e.g., HIV, HCV, HBV)
+0.0001%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov